Dealing with refractoriness in obstetric primary antiphospholipid syndrome

Abstract

Get full access to this article

View all access options for this article.

References

Alijotas-Reig

. Treatment of refractory obstetric antiphospholipid syndrome: The state of the art and new trends in the therapeutic management. Lupus 2013; 22: 6–17.

Guller

Rand

. Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. Am J Obstet Gynecol 2011; 205: 576.e7–e14.

Rand

Quinn

. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: Evidence for a novel effect for an old antimalarial drug. Blood 2010; 115: 2292–2299.

Bramham

Thomas

Nelson-Piercy

. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 2011; 117: 6948–6951.

Rivaroxaban in Antiphospholipid Syndrome (RAPS) trial, http://www.controlled-trials.com/ISRCTN68222801 (accessed 20 February 2014).

Erkan

Vega

Ramón

Kozora

Lockshin

. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum 2013; 65: 464–471.

Shamonki

Salmon

Hyjek

Baergen

. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007; 196: 167.e1–e5.

Lonze

Zachary

Magro

. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 2014; 14: 459–465.

Dealing with refractoriness in obstetric primary antiphospholipid syndrome—often not a matter of success

Abstract

Get full access to this article

References